Unity Biotechnology, Inc. (UNBX)
Unity Biotechnology, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $0.06, up 0.00% on the session, giving a market capitalisation of $965,603. On trailing twelve-month figures it carries a trailing P/E of -0.13, a net margin of 0.0%. Its beta of 1.19 implies it has historically moved more than the broad market.
Unity Biotechnology, Inc. functions as a biotechnology enterprise dedicated to creating innovative treatments aimed at slowing down, stopping, or even reversing illnesses associated with the aging process. A core component of their therapeutic development involves senolytic compounds, specifically designed to address various ocular (eye) and neurological conditions.
Unity Biotechnology, Inc. is most often compared with the following Healthcare names: